InspireMD (NSPR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Voting matters and shareholder proposals
Proposal 2 seeks approval to amend the Certificate of Incorporation to increase authorized common stock from 150 million to 250 million shares.
Proposal 2 is classified as a “routine” matter, allowing brokers to vote uninstructed shares at their discretion under NYSE rules.
Brokers cannot vote uninstructed shares for the Director Election Proposal (Proposal 1) or the Adjournment Proposal (Proposal 4).
Brokers have discretionary authority to vote on the Auditor Reappointment Proposal (Proposal 3) as it is also considered “routine.”
Broker non-votes are counted for quorum but have no effect on the outcome of Proposals 1–4.
Shareholder rights and capital structure
The proposed amendment would increase the number of authorized shares of common stock, potentially impacting future capital raising and shareholder dilution.
Latest events from InspireMD
- Innovative stent and CMS changes accelerate a stent-first shift in carotid intervention.NSPR
25th Annual Needham Virtual Healthcare Conference23 Apr 2026 - Votes sought for director elections, share increase, auditor ratification, and meeting adjournment.NSPR
Proxy filing20 Apr 2026 - Proxy seeks approval for director elections, share increase, auditor ratification, and meeting adjournment.NSPR
Proxy filing20 Apr 2026 - Proxy covers director elections, share increase, auditor reappointment, and governance updates.NSPR
Proxy filing10 Apr 2026 - Q4 2025 revenue jumped 62% year-over-year, with 2026 growth projected at up to 65%.NSPR
Q4 202518 Mar 2026 - Q2 revenue up 5.4% with best-in-class trial results and $17.9M raised for U.S. launch.NSPR
Q2 20242 Feb 2026 - Q3 revenue up 16.3% to $1.81M; net loss widened; U.S. launch targeted for H1 2025.NSPR
Q3 202415 Jan 2026 - Q4 revenue up 10.7%, losses widen, and U.S. CGuard Prime launch expected in H1 2025.NSPR
Q4 202426 Dec 2025 - $200M shelf registration with $75M ATM equity offering to fund growth; dilution risk is significant.NSPR
Registration Filing16 Dec 2025